T cell therapies, which use genetically-engineered T cells of the human immune system as therapeutics, are revolutionizing medical oncology by effectively treating previously incurable blood cancers. However, their success against solid tumors has been…
Progenitor exhausted CD8+ T (Tpex) cells have emerged as a pivotal component in tumor immunotherapy due to their unique ability to self-renew and rapidly proliferate. These cells have shown promise in expanding and differentiating into functional exhau…
For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells. However, success has been limited due to the technological challenge of engineering therapies tha…
An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy designed to treat the most deadly skin cancer, a study…
QIMR Berghofer researchers have developed super-charged immune cells that could potentially improve glioblastoma survival by fighting the deadly brain cancer and preventing its recurrence.
Using zebrafish “avatars,” an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López—a former Ph.D. student at the lab now working at the Universidad de…
The complex dynamics between liver cancer stem cells (CSCs) and immune cells within the tumor microenvironment (TME) are central to the progression of liver cancer. These interactions are critical in creating an immunosuppressive setting that significa…
By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments.
A protein called Meteorin-like (METRNL) in the tumor microenvironment saps energy from T cells, thereby severely limiting their ability to fight cancer, according to new research directed by investigators at the Johns Hopkins University School of Medic…
A research paper has been published in Oncotarget titled, “INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogeni…
